Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Price to Sales Ratio (P/S) on December 30, 2024

Clearmind Medicine Inc. Price to Sales Ratio (P/S) is NA on December 30, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Clearmind Medicine Inc. 52-week high Price to Sales Ratio (P/S) is NA on December 30, 2024, which is NA below the current Price to Sales Ratio (P/S).
Clearmind Medicine Inc. 52-week low Price to Sales Ratio (P/S) is NA on December 30, 2024, which is NA below the current Price to Sales Ratio (P/S).
Clearmind Medicine Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years